Nectar Lifesciences Limited (NECLIFE) Fair Value & Analysis
Healthcare · IN · Market cap ₹2.3B
Fair value as of: Jul 3, 2026
From 3 valuation models · updated today
Share price −2.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹9.30 – ₹23.13 · fair‑value band ₹7.26 – ₹13.75 · the ₹11.75 price screens above the ₹11.00 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Nectar Lifesciences Limited (NECLIFE) currently trades at ₹11.75, while our model-based Fair Value estimate is ₹11.00 — implying the stock looks roughly 6.4% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at ₹92.9M. It earns a return on equity of -7.5%. The balance sheet holds a net cash position of ₹1.1B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Nectar Lifesciences Limited reported revenue of ₹20.1M in FY2026 versus ₹16.7B in FY2022, a compound −81.4%/yr. Reported net income was −₹2.9B in FY2026.
Is NECLIFE fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nectar Lifesciences Limited (NECLIFE) undervalued?
What is the fair value of NECLIFE?
What is the quality score of NECLIFE?
What is the revenue of Nectar Lifesciences Limited (NECLIFE)?
What is the net profit margin of NECLIFE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.